ZUG, Switzerland, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to...
ASLAN to receive $20 million in financing with the potential to receive up to an additional $80 million for an...
The TRials with EblasaKimab in Atopic Dermatitis (TREK-AD) study has enrolled the final patient Topline results expected in early July...
PRESS RELEASE - REGULATED INFORMATION 24 February 2023, 07:00 CET Biocartis Creates New Share Option Plan and Cancels Outstanding Pool...
— Company expects to announce data for Factor VIII expression in non-human primates in 2023 — Strong cash balance of...
CHATHAM, N.J., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage...
Advanced RLY-4008: Reported interim data with 88% overall response rate at pivotal dose and 63% across all doses in pan-FGFR...
Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Feb. 23, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK)...
– Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with...
Preclinical data demonstrate potential to orally deliver peptides and monoclonal antibodies at bioavailability levels more than double the company’s current...
Providence, RI, Feb. 23, 2023 (GLOBE NEWSWIRE) -- As previously announced, Ocean Biomedical, Inc. (NASDAQ: OCEA) celebrates the discovery of...
Following the IND clearance, the Company is advancing into a Phase 1 clinical studyPotentially addressing most common subtypes of adenocarcinoma...
Company Focuses on Development of Neuromuscular Blocking Agents Phase II Randomized Trial for BX1000 Initiated, Positive Interim Results Announced; Completion...
Positive Phase 3 MAESTRO-NASH study results reported in December 2022 position Madrigal for a resmetirom new drug application filing in...
Allows Endovascular Procedure to be Performed from the Cath-Lab Control Room, Potentially Minimizing Radiation Exposure and Reducing Physical Strain for...
-Initiated and completed enrollment for EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis; topline data expected 2Q23- -Launched EMERALD-2...
Strong Conclusion to 2022 – Q4’22 Revenue Highest Since Start of COVID-19 Pandemic Record Quarterly MyoCycle Sales Supplement Improved Exoskeleton...
Record Fourth Quarter Total Revenue of $52.7 Million and 31% Net Income Growth Full-Year 2022 Total Revenue of $164.4 Million,...
NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced...
–Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) continues to have high operating fidelity; month 30...